E Felip

Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-smal...

Annals of oncology : official journal of the European Society for Medical Oncology · 2025-07

A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab as e...

Annals of oncology : official journal of the European Society for Medical Oncology · 2025-05

Amivantamab plus lazertinib versus osimertinib als eerstelijns bij EGFR-gemuteerd NSCLC: MARIPOSA fase III

Annals of oncology : official journal of the European Society for Medical Oncology · 2024-09

Amivantamab plus chemo met en zonder lazertinib bij EGFR-gemuteerd NSCLC: MARIPOSA-2 fase III

Annals of oncology : official journal of the European Society for Medical Oncology · 2024-01

OS met adjuvant atezolizumab na chemotherapie bij NSCLC: IMpower010 OS

Annals of oncology : official journal of the European Society for Medical Oncology · 2023-10

OSE2101 kankervaccin versus chemotherapie bij HLA-A2-positief NSCLC: fase III

Annals of oncology : official journal of the European Society for Medical Oncology · 2023-10

Subcutaan atezolizumab: IMscin001 fase III farmacokinetiek

Annals of oncology : official journal of the European Society for Medical Oncology · 2023-08

EGFR-gemuteerd NSCLC: ESMO expertconsensus

Annals of oncology : official journal of the European Society for Medical Oncology · 2022-05

Pemetrexed-platina met of zonder pembrolizumab bij NSCLC: KEYNOTE-789 fase III

Annals of oncology : official journal of the European Society for Medical Oncology · 2021-07

Archief- versus vers tumormateriaal voor PD-L1 en OS bij NSCLC: OAK analyse

Annals of oncology : official journal of the European Society for Medical Oncology · 1 februari 2019

Eribuline versus physician's choice bij gevorderd NSCLC: gerandomiseerde fase III-studie

Annals of oncology : official journal of the European Society for Medical Oncology · 1 september 2017

Pembrolizumab als eerstelijns bij PD-L1-positief gevorderd NSCLC: fase I KEYNOTE-001 resultaten

Annals of oncology : official journal of the European Society for Medical Oncology · 1 april 2017

Systematische evaluatie van pembrolizumab-dosering bij patiënten met gevorderd NSCLC

Annals of oncology : official journal of the European Society for Medical Oncology · 2016-07